The strategy to control New Zealand's epidemic of group B meningococcal disease

Pediatric Infectious Disease Journal

Volumn 23, Issue 12 SUPPL., 2004, Pages

  O'Hallahan, Jane ^a   Lennon, Diana ^b   Oster, Philipp ^c  

^a MINISTRY OF HEALTH   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c CHIRON VACCINES   (Italy)

Author keywords

Epidemic; Neisseria meningitidis; New zealand; Outer membrane vesicle vaccines; Serogroup B meningococcal disease

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL MEMBRANE; CONTROLLED STUDY; DRUG SYNTHESIS; EPIDEMIC; GOVERNMENT; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; MASS IMMUNIZATION; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEW ZEALAND; NORWAY; OUTER MEMBRANE; PHYSICAL CHEMISTRY; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT PLANNING; ABORIGINE; ETHNOLOGY; IMMUNOLOGY; INFANT; NEWBORN; PREVENTIVE HEALTH SERVICE;

CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND; OCEANIC ANCESTRY GROUP;

EID: 16544393141     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000147645.53942.00     Document Type: Article

References (35)

1. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health. 2001;37:S13-S19.
2. Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J. Meningococcal disease. N Engl J Med. 2001;344:1378-1388.
3. Martin D, McDowell R, Sneyd E, Baker M. The Epidemiology of Meningococcal Disease in New Zealand in 2002: Report Prepared for the Ministry of Health by the Institute of Environmental Research Limited (ESR). Wellington, New Zealand: Ministry of Health; 2003.
4. Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J. 2000;19:333-345.
5. Jodar L, Feavers I, Salisbury D, Granoff D. Development of vaccines against meningococcal disease. Lancet. 2002;359:1499-1508.
6. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis. 1994;169:847-852.
7. Gold R, Lepow ML, Goldschneider I, Gotschlich EC. Immune response of human infants to polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis. 1977;136(suppl):S31-S35.
8. Goldschneider I, Lepow ML, Gotschlich EC. Immunogenicity of the group A and group C meningococcal polysaccharides in children. J Infect Dis. 1972;125:509-519.
9. Goldschneider I, Lepow ML, Gotschlich EC, Mauck FT, Bachl F, Randolph M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis. 1973;128:769-776.
10. Reingold A, Broome CV, Hightower A, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;2:114-118.
11. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotschlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis. 1979;140:690-697.
12. Käyhty H, Karanko V, Peltola H, Sarna S, Mäkelä H. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis. 1980;142:861-868.
13. Ramsay M, Andrews N, Kaczmarski E, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357:195-196.
14. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283:2795-2801.
15. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186:1353-1357.
16. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated versus plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA. 1998;280:1685-1689.
17. MacDonald NE, Halperin S, Law B, Danzig L, Granoff D. Safety and immunogenicity of meningococcal C conjugated (MenC) vaccine in toddlers previously immunized with meningococcal polysaccharide (MenPS) vaccine. Pediatr Res. 1999;45:167A. Abstract 976.
18. McVernon J, MacLennan J, Buttery J, Oster P, Danzig L, Moxon ER. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J. 2002;21:747-753.
19. 197 in United States infants. Pediatr Infect Dis J. 2001;20:153-159.
20. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179:1569-1572.
21. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163.
22. Richmond P, Borrow R, Findlow J, et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun. 2001;69:2378-2382.
23. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281:1520-1527.
24. Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126:514-521.
25. Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J. 2000;19:983-990.
26. De Wals P, Deceuninck G, Boulianne N, Serres G. Impact of a mass immunization campaign against serogroup C meningococcal disease in 2001-2002, Province of Quebec, Canada. Int J Infect Dis. 2004;8(suppl 1):S190.
27. Sierra GV, Campa HC, Varca-cel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195-210.
28. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093-1096.
29. Zollinger WD, Boslego J, Moran E, et al. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH Ann. 1991;14:211-213.
30. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1. 3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 1995;13:821-829.
31. De Moraes J, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074-1078.
32. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994;62:4419-4424.
33. New Zealand Ministry of Health. The Meningococcal B Immunisation Programme: A Response to an Epidemic: National Implementation Strategy. Wellington, New Zealand: New Zealand Ministry of Health; 2004.
34. New Zealand Ministry of Health. Fact Sheet 6: The Search for a Group B Meningococcal Disease Vaccine. Wellington, New Zealand: New Zealand Ministry of Health; 2004.
35. Holst J, Aaberge IS, Oster P, et al. A 'tailor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurveill Wkly. 2003;7:6-9.